BOARD OF DIRECTORS APPOINTS CHARLES J. BRAMLAGE NEW PRESIDENT AND CEO OF BATTELLEPHARMA

BattellePharma Media Contact:
Christy Polsley-Finch
(614) 340-2361
finch@battellepharma.com

COLUMBUS, Ohio - BattellePharma, a pre-public specialty pharmaceutical company, today announced the promotion of Charles J. Bramlage as the company's next President and CEO, effective immediately. Bramlage will succeed Dennis B. Cearlock, who will leave BattellePharma to become the President, CEO, and Board Chairman of Zivena, a new company formed from BattellePharma in November, 2002, focusing on inhaled oncology products.

Bramlage joined BattellePharma in April, 2001 as the Senior Vice President and General Manager, Specialty Pharmaceuticals where he has been responsible for building the future drug delivery business and new pulmonary drug product franchises. Prior to that, he served in executive positions at GlaxoSmithKline including Vice President of Respiratory Commercial Global Development in London, England where he was responsible for the global launch of Seretide in 1999. From 1995-1998, he served as Vice President of U.S. Respiratory and Cardiovascular Marketing in Research Triangle Park, North Carolina where he was responsible for the U.S. launch of Flovent in 1996. Under his leadership, Flovent, Serevent, and Flonase all became the leaders in their respective market segments. He also served as Director of the Oncology Products for GSK in 1994 and 1995. Bramlage received his BA in Business Administration from The Ohio State University and an MBA in Finance from the University of Dayton.

"Chuck Bramlage is the right person to take BattellePharma through the next development stage," said Dennis Cearlock. "BattellePharma was fortunate to attract an individual with Chuck's potential. He has proven to be very effective in networking with BattellePharma's pharmaceutical company partners and the financial community and he is committed to superior execution."

"BattellePharma has a tremendous opportunity to make a huge difference for patients by introducing improved medicines using MysticTM drug inhalation technology to expand the safety and ease of administration of existing drugs and revolutionize the treatment of respiratory and systemic diseases," stated Chuck Bramlage. "I look forward to working with the BattellePharma team and our partners to achieve superior patient benefits in numerous products using Mystic technology. Through this effort, we will also reach our founder Dennis Cearlock's vision for this technology."

About BattellePharma

BattellePharma is a pre-public specialty pharmaceutical company leveraging science and technology to design more effective medicines. BattellePharma's products are based on two platform technologies: Mystic inhalation technology and novel formulation technologies therapy. The company develops products by combining these platforms with novel or generic compounds to create therapies to treat respiratory and systemic diseases. BattellePharma has partnerships with numerous pharmaceutical corporations including Abbott Laboratories, Corus Pharma Inc., GlaxoSmithKline, Pfizer Inc., Pharmacia Corporation, Viasys Healthcare, and ViroPharma Inc, and is a subsidiary of Battelle, the world's largest independent and private research and development organization. For more information on BattellePharma, reference the company's website at www.battellepharma.com.

About Zivena

Zivena is an emerging specialty pharmaceutical company focused on developing inhaled oncology products. The Company's strategy is to become a successful, integrated specialty pharmaceutical company by developing a suite of highly differentiated drugs that will be used to create and maintain leadership in a new, multi-billion dollar market - inhaled oncolytics for treating primary and metastatic lung tumors. The Company's first product, Resmycin (doxorubicin HCl inhalation solution) is in late stage Phase I clinical testing and is showing positive signs of efficacy. The targeted launch date for the Resmycin product is first quarter 2006. Zivena is also a subsidiary of Battelle. For more information on Zivena, contact Katy Delaney at (614) 424-5544 or at delaneyk@battelle.org.